We are RenuMemo Therapeutics, a leading biopharmaceutics company,
committed to discovering and developing drugs for the treatment of Alzheimer’s disease.
We have integrated technologies for botanical drugs and chemical drugs.
Our team is capable of identification, quality control, preclinical evaluation, and clinical designs.
Alzheimer’s disease (AD) is increasingly affecting the aging population worldwide.
In the United States, there are 6.2 million people that suffers from the disease; globally, it is 50 million that is being affected. The number is expected to increase only if effective interventions and treatments are not successful. The accumulated research evidence indicates that the complexity and challenges of Alzheimer’s disease has multiple pathological causes. Currently, single target therapeutics might not be as effective.
The primary pathological hallmarks for Alzheimer’s disease include amyloid plaques, neurofibrillary tangles, that is primarily composed of hyperphosphorylated tau protein and the neuroinflammation, which related to amyloid and tau.
The goal of RenuMemo therapeutics is to provide effective treatment that targets multiple pathology by several approaches:
- utilize multiple medicinal herbs,
- use multiple chemical compounds.